81. A report should be submitted to the Vaccine Adverse Event Reporting System (VAERS) if a patient experiences a significant side effect after the administration of:
Answer: A
A report should be submitted to the Vaccine Adverse Event Reporting System (VAERS) if a patient experiences a significant side effect after the administration of Twinrix.
Submitting a report to VAERS is essential when a patient has a significant adverse event following the administration of a vaccine, such as Twinrix, which is a combination vaccine for hepatitis A and B.
A) Twinrix
Twinrix is a vaccine that combines hepatitis A and hepatitis B vaccines. Significant side effects occurring after its administration should be reported to VAERS to ensure patient safety and monitor vaccine-related adverse effects, making it the correct choice.
B) Topamax
Topamax, or topiramate, is an anticonvulsant medication used for epilepsy and migraine prevention. While it may have side effects, it is not a vaccine, and therefore does not require reporting to VAERS. This option is incorrect.
C) Tenormin
Tenormin, known generically as atenolol, is a beta-blocker used to treat hypertension and heart issues. Similar to Topamax, it is a medication and not a vaccine, meaning any side effects experienced would not be reported to VAERS. Thus, this option is also incorrect.
D) Tricor
Tricor, or fenofibrate, is a medication used to lower cholesterol levels. As with the other medications listed, it does not fall under the category of vaccines, and adverse events related to its use would not be reported to VAERS. Therefore, this option is incorrect as well.
Conclusion
The need to report significant side effects to VAERS specifically applies to vaccines, such as Twinrix, making it the correct answer. In contrast, the other options are all medications that do not require VAERS reporting, highlighting the unique role of vaccines in public health monitoring.